Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hefter

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Journal of Neural Transmission (Vienna, Austria : 1996)|August 18, 2012
Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapyWolfgang H Jost, Harald Hefter, Andrea Stenner, et al.
Journal of Neurology|July 12, 2002
Central and peripheral nervous system functions are independently disturbed in HIV-1 infected patientsHans-Jürgen von Giesen, Hubertus Köller, Harald Hefter, et al.
Toxins|August 6, 2021
The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical DystoniaHarald Hefter, Isabelle Schomaecker, Max Schomaecker, et al.
Journal of Neurology|January 22, 2020
Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional studyHarald Hefter, Raphaela Brauns, Beyza Ürer, et al.
Genes|July 27, 2022
Different Response Behavior to Therapeutic Approaches in Homozygotic Wilson's Disease Twins with Clinical Phenotypic Variability: Case Report and Literature ReviewSara Samadzadeh, Theodor Kruschel, Max Novak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2003
Secondary progressive chronic manganism associated with markedly decreased striatal D2 receptor densityKirn R Kessler, Gilbert Wunderlich, Harald Hefter, et al.
BMJ Open|August 7, 2012
Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins--a single cohort 4-year follow-up studyHarald Hefter, Christian Hartmann, Ulrike Kahlen, et al.
Pain Medicine (Malden, Mass.)|June 23, 2011
Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections?Reiner Benecke, Axel Heinze, Gerhard Reichel, et al.
Toxins|August 6, 2021
Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot DropHarald Hefter, Werner Nickels, Dietmar Rosenthal, et al.
Medicina (Kaunas, Lithuania)|January 21, 2022
The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot StudyHarald Hefter, Isabelle Schomaecker, Max Schomaecker, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Journal of Neural Transmission (Vienna, Austria : 1996)|August 18, 2012
Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapyWolfgang H Jost, Harald Hefter, Andrea Stenner, et al.
Journal of Neurology|July 12, 2002
Central and peripheral nervous system functions are independently disturbed in HIV-1 infected patientsHans-Jürgen von Giesen, Hubertus Köller, Harald Hefter, et al.
Toxins|August 6, 2021
The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical DystoniaHarald Hefter, Isabelle Schomaecker, Max Schomaecker, et al.
Journal of Neurology|January 22, 2020
Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional studyHarald Hefter, Raphaela Brauns, Beyza Ürer, et al.
Genes|July 27, 2022
Different Response Behavior to Therapeutic Approaches in Homozygotic Wilson's Disease Twins with Clinical Phenotypic Variability: Case Report and Literature ReviewSara Samadzadeh, Theodor Kruschel, Max Novak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2003
Secondary progressive chronic manganism associated with markedly decreased striatal D2 receptor densityKirn R Kessler, Gilbert Wunderlich, Harald Hefter, et al.
BMJ Open|August 7, 2012
Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins--a single cohort 4-year follow-up studyHarald Hefter, Christian Hartmann, Ulrike Kahlen, et al.
Pain Medicine (Malden, Mass.)|June 23, 2011
Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections?Reiner Benecke, Axel Heinze, Gerhard Reichel, et al.
Toxins|August 6, 2021
Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot DropHarald Hefter, Werner Nickels, Dietmar Rosenthal, et al.
Medicina (Kaunas, Lithuania)|January 21, 2022
The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot StudyHarald Hefter, Isabelle Schomaecker, Max Schomaecker, et al.
Pageof 8